Renaud Ronald C Jr - Net Worth and Insider Trading

Renaud Ronald C Jr Net Worth

The estimated net worth of Renaud Ronald C Jr is at least $0 dollars as of 2023-03-23. Renaud Ronald C Jr is the CEO of Translate Bio Inc and owns about 0 shares of Translate Bio Inc (TBIO) stock worth over $0. Details can be seen in Renaud Ronald C Jr's Latest Holdings Summary section.

Transaction Summary of Renaud Ronald C Jr

Renaud Ronald C Jr Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Renaud Ronald C Jr owns 7 companies in total, including Atara Biotherapeutics Inc (ATRA) , Translate Bio Inc (TBIO) , and Chimerix Inc (CMRX) among others .

Click here to see the complete history of Renaud Ronald C Jr’s form 4 insider trades.

Insider Ownership Summary of Renaud Ronald C Jr

Ticker	Comapny	Transaction Date	Type of Owner
ATRA	Atara Biotherapeutics Inc	2021-06-08	director
TBIO	Translate Bio Inc	2020-03-03	director & Chief Executive Officer & other: President
CMRX	Chimerix Inc	2014-12-17	director
AKBA	Akebia Therapeutics Inc	2014-09-12	director
PTCT	PTC Therapeutics Inc	2017-01-03	director
KERX	Keryx Biopharmaceuticals Inc	2007-02-14	Chief Financial Officer
IKNA	Ikena Oncology Inc	2021-03-25	director

Renaud Ronald C Jr Latest Holdings Summary

Renaud Ronald C Jr currently owns a total of 1 stock. Renaud Ronald C Jr owns 0 shares of Translate Bio Inc (TBIO) as of September 14, 2021, with a value of $0.

Latest Holdings of Renaud Ronald C Jr

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TBIO	Translate Bio Inc	2021-09-14	0	37.36	0

Holding Weightings of Renaud Ronald C Jr

Renaud Ronald C Jr Form 4 Trading Tracker

According to the SEC Form 4 filings, Renaud Ronald C Jr has made a total of 1 transactions in Translate Bio Inc (TBIO) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Translate Bio Inc is the sale of 954,053 shares on September 14, 2021, which brought Renaud Ronald C Jr around $36 Million.

Insider Trading History of Renaud Ronald C Jr

Ticker
TBIO
AKBA

Ticker	Company	Date	Buy/Sell	Insider Trading Shares	Shares Change	Price	Cost	Final Share	Current Price	Price Change Since Insider Trade (%)	Filing Date
Ticker	Company	Date	Buy/Sell	Insider Trading Shares	Shares Change	Price	Cost	Final Share	Current Price	Price Change Since Insider Trade (%)	Filing Date
TBIO	Translate Bio Inc	2021-09-14	Sell	954,053.00	-100.00%	$38.00	$36,254,000.00	0	$37.36	-1.68%	-
AKBA	Akebia Therapeutics Inc	2014-12-02	Buy	5,000.00	100.00%	$11.92	$59,600.00	5,000.00	$0.69	-94.25%	-

Total 2

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Renaud Ronald C Jr Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Renaud Ronald C Jr Ownership Network

Ownership Network List of Renaud Ronald C Jr

No Data

Ownership Network Relation of Renaud Ronald C Jr

Renaud Ronald C Jr Owned Company Details

What does Atara Biotherapeutics Inc do?

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Who are the key executives at Atara Biotherapeutics Inc?

Renaud Ronald C Jr is the director of Atara Biotherapeutics Inc. Other key executives at Atara Biotherapeutics Inc include EVP & Chief Technical Officer Charlene A. Banard , Chief Commercial Officer Kristin Yarema , and SVP & GC & Secretary Amar Murugan .

Atara Biotherapeutics Inc (ATRA) Insider Trades Summary

Over the past 18 months, Renaud Ronald C Jr made no insider transaction in Atara Biotherapeutics Inc (ATRA). Other recent insider transactions involving Atara Biotherapeutics Inc (ATRA) include a net sale of 42,900 shares made by Utpal Koppikar , a net sale of 36,833 shares made by Jakob Dupont , and a net sale of 91,439 shares made by Pascal Touchon .

In summary, during the past 3 months, insiders sold 34,330 shares of Atara Biotherapeutics Inc (ATRA) in total and bought 0 shares, with a net sale of 34,330 shares. During the past 18 months, 214,045 shares of Atara Biotherapeutics Inc (ATRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 214,045 shares.

Atara Biotherapeutics Inc (ATRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:ATRA Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Translate Bio Inc do?

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Who are the key executives at Translate Bio Inc?

Renaud Ronald C Jr is the director & Chief Executive Officer & other: President of Translate Bio Inc. Other key executives at Translate Bio Inc include 10 percent owner Takeda Pharmaceutical Co Ltd , 10 percent owner Shire Human Genetic Therapies, Inc. , and 10 percent owner Seth A Klarman .

Translate Bio Inc (TBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Translate Bio Inc (TBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Translate Bio Inc (TBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Translate Bio Inc (TBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:TBIO Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Chimerix Inc do?

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Who are the key executives at Chimerix Inc?

Renaud Ronald C Jr is the director of Chimerix Inc. Other key executives at Chimerix Inc include Chief Medical Officer Allen S. Melemed , 10 percent owner Cantex Pharmaceuticals, Inc. , and Principal Accounting Officer David Jakeman .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Renaud Ronald C Jr made no insider transaction in Chimerix Inc (CMRX). Other recent insider transactions involving Chimerix Inc (CMRX) include a net sale of 15,520 shares made by David Jakeman , a net purchase of 40,000 shares made by Fred A Middleton , and a net purchase of 15,000 shares made by Michael T. Andriole .

In summary, during the past 3 months, insiders sold 3,230 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 3,230 shares. During the past 18 months, 15,520 shares of Chimerix Inc (CMRX) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 49,480 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:CMRX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Akebia Therapeutics Inc do?

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Who are the key executives at Akebia Therapeutics Inc?

Renaud Ronald C Jr is the director of Akebia Therapeutics Inc. Other key executives at Akebia Therapeutics Inc include SVP & Chief Accounting Officer Violetta Cotreau , SVP & CFO and Treasurer David A Spellman , and SVP & Chief Medical Officer Steven Keith Burke .

Akebia Therapeutics Inc (AKBA) Insider Trades Summary

Over the past 18 months, Renaud Ronald C Jr made no insider transaction in Akebia Therapeutics Inc (AKBA). Other recent insider transactions involving Akebia Therapeutics Inc (AKBA) include a net sale of 22,809 shares made by Steven Keith Burke , a net sale of 130,500 shares made by John P. Butler , and a net sale of 30,502 shares made by Michel Dahan .

In summary, during the past 3 months, insiders sold 217,124 shares of Akebia Therapeutics Inc (AKBA) in total and bought 0 shares, with a net sale of 217,124 shares. During the past 18 months, 228,671 shares of Akebia Therapeutics Inc (AKBA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 228,671 shares.

Akebia Therapeutics Inc (AKBA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:AKBA Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does PTC Therapeutics Inc do?

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Who are the key executives at PTC Therapeutics Inc?

Renaud Ronald C Jr is the director of PTC Therapeutics Inc. Other key executives at PTC Therapeutics Inc include Chief Business Officer Eric Pauwels , Chief Development Officer Matthew B. Klein , and Chief Financial Officer Emily Luisa Hill .

PTC Therapeutics Inc (PTCT) Insider Trades Summary

Over the past 18 months, Renaud Ronald C Jr made no insider transaction in PTC Therapeutics Inc (PTCT). Other recent insider transactions involving PTC Therapeutics Inc (PTCT) include a net sale of 32,689 shares made by Mark Elliott Boulding , a net sale of 14,053 shares made by Stuart Walter Peltz , and a net sale of 12,118 shares made by Emily Luisa Hill .

In summary, during the past 3 months, insiders sold 26,035 shares of PTC Therapeutics Inc (PTCT) in total and bought 0 shares, with a net sale of 26,035 shares. During the past 18 months, 94,413 shares of PTC Therapeutics Inc (PTCT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 94,413 shares.

PTC Therapeutics Inc (PTCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:PTCT Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Keryx Biopharmaceuticals Inc do?

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Who are the key executives at Keryx Biopharmaceuticals Inc?

Renaud Ronald C Jr is the Chief Financial Officer of Keryx Biopharmaceuticals Inc. Other key executives at Keryx Biopharmaceuticals Inc include director & Interim CEO Jodie Pope Morrison , Chief Financial Officer Scott A Holmes , and 10 percent owner Seth A Klarman .

Keryx Biopharmaceuticals Inc (KERX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Keryx Biopharmaceuticals Inc (KERX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Keryx Biopharmaceuticals Inc (KERX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Keryx Biopharmaceuticals Inc (KERX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:KERX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Ikena Oncology Inc do?

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.

Who are the key executives at Ikena Oncology Inc?

Renaud Ronald C Jr is the director of Ikena Oncology Inc. Other key executives at Ikena Oncology Inc include CFO & Head of Corp. Dev. Jotin Marango , Principal Accounting Officer Francisco Oliveira , and Chief Scientific Officer Xiaoyan Michelle Zhang .

Ikena Oncology Inc (IKNA) Insider Trades Summary

Over the past 18 months, Renaud Ronald C Jr made no insider transaction in Ikena Oncology Inc (IKNA). Other recent insider transactions involving Ikena Oncology Inc (IKNA) include a net sale of 2,000 shares made by Xiaoyan Michelle Zhang , a net sale of 26,278 shares made by Jean Francois Formela , and a net sale of 26,278 shares made by Atlas Venture Fund Xi, L.p. .

In summary, during the past 3 months, insiders sold 0 shares of Ikena Oncology Inc (IKNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 54,556 shares of Ikena Oncology Inc (IKNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 54,556 shares.

Ikena Oncology Inc (IKNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:IKNA Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

Renaud Ronald C Jr Mailing Address

Above is the net worth, insider trading, and ownership report for Renaud Ronald C Jr. You might contact Renaud Ronald C Jr via mailing address: C/o Idenix Pharmaceuticals, Inc., 60 Hampshire Street, Cambridge Ma 02109.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF ADV Part 2A ADV Part 2B ADV Part 3 Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.